References
- Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases 1967; 20: 637–648.
- Fisher LD, Dixon, DO et al. Intention-to- treat in clinical trials. In: Peace KE (Ed.). Statistical Issues in Drug Research and Development. Marcel Dekker, 1990.
- Ellenberg JH. Intent-to-treat analysis versus as-treated analysis. Drug Information Journal 1996; 30: 535–544.
- Ebbutt AF, Firth L. Practical issues in equivalence trials. Statistics in Medicine 1998; 7: 1691–1701.
- Matilde Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Statistics in Medicine 2006; 25(7): 1169–1181.
- Sheiner LB. Is intent-to-treat analysis always (ever) enough? British Journal of Clinical Pharmacology 2000; 54: 203–211.
- Lachin JM. Statistical considerations in the intent-to-treat principle. Controlled Clinical Trials 2000; 21: 167–189.
- Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Journal of the American Medical Association 1996; 276(8):637–639.
- Sackett D, Gent M. Controversy in counting and attributing events in clinical trials. New England Journal of Medicine 1979; 301: 1410–1412.
- Hlatky MA, Owens DK, Sanders GD. Cost- effectiveness as an outcome in randomized clinical trials. Clinical Trials 2006; 3: 543–551.